← Back to Search

NMDA Receptor Antagonist

Intranasal Ketamine (IN) for Depression (SURE-ECT Trial)

N/A

Waitlist Available

Led By Yuliya Knyahnytska, MD, PhD

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 months

Awards & highlights

SURE-ECT Trial Summary

This trial aims to study the effects of intranasal ketamine on patients with ultra-resistant depression, who have not responded to other treatments.

Eligible Conditions

Depression

SURE-ECT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in symptom severity of depression as measured by the Hamilton Rating Scale for Depression - 24

Secondary outcome measures

Change in symptom severity of Suicidal Ideation as measured by by the Scale of Suicide Ideation (SSI)

Impact of Ketamine on cortical excitation as measured by intracortical facilitation (ICF)

Impact of Ketamine on cortical inhibition as measured by short-interval cortical inhibition (SICI)

+4 more

Other outcome measures

Change in quality of life measures as assessed by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

SURE-ECT Trial Design

1Treatment groups

Experimental Treatment

Group I: Intranasal Ketamine (IN)Experimental Treatment1 Intervention

Ketamine will be administered intranasally (IN) using an atomizer (MAD300 by Teleflex, North Carolina, USA).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Intranasal Ketamine (IN)

2021

N/A

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor

354 Previous Clinical Trials

81,095 Total Patients Enrolled

84 Trials studying Depression

19,102 Patients Enrolled for Depression

Yuliya Knyahnytska, MD, PhDPrincipal InvestigatorCentre for Addiction and Mental Health

1 Previous Clinical Trials

30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor seeking out participants over the age of 45?

"According to the inclusion criteria, only individuals aged 21-65 are eligible for this trial. An additional 204 medical studies exist with age limits lower than 18 and 1044 trials are available for those above 65 years old."

Answered by AI

Are there any current opportunities to join this clinical experiment?

"Affirmative. According to clinicaltrials.gov, this research is actively recruiting participants with the trial having been first posted on October 25th 2021 and last updated on December 9th 2021. The team behind this study are in need of 25 volunteers from a single site."

Answered by AI

Am I able to enroll in this experiment?

"This clinical trial seeks 25 adults, between 21 and 65 years of age, with clinically diagnosed major depressive disorder (MDD). Candidates must have had at least 8 convulsive therapy sessions but did not respond to it or were unable to bear the treatment. Only outpatients that are able to provide informed consent along with exhibiting a score higher than 14 on their HRSD-24 test can be considered for enrolment into this medical experiment."

Answered by AI

What is the upper limit for participants in the current clinical trial?

"Affirmative. Clinicaltrials.gov's records reveal that this medical study, which was first published on October 25th 2021, is actively seeking recruits. In total, 25 volunteers are required for the clinical trial at a single location."

Answered by AI

What outcomes is this clinical trial attempting to demonstrate?

"The principal objective of this two-month study is to detect ameliorations in depression severity as measured with the Hamilton Rating Scale for Depression - 24. Additionally, investigations on cortical excitation through Transcranial magnetic stimulation (TMS) paired with electromyography (EMG) and electroencephalography (EEG), blood pressure changes before treatment and every 30 minutes within a 2-hour monitoring period, and any adverse events connected to the use of intranasal ketamine will be closely monitored as secondary outcomes."

Answered by AI